Biotech and Pharmaceuticals Pharmaceuticals

  • swine_flu_needle_200.jpg

    When I went to the FDA's Web site today I was surprised to see on the homepage a link to a letter written by Commissioner Dr. Peggy Hamburg. It's addressed to "Dear Healthcare Professional" aka a "Dear Doctor letter." That's a common type of communication from the agency and/or companies to the medical community, usually when they've got bad news to pass along about a drug or device. It's pretty rare for the commish to write one.

  • Health Care Reform

    Many analysts, lobbyists and industry executives have been saying for months that healthcare reform would probably end up being a net positive for the drug companies.

  • doctor

    It appears that Washington is about to enact sweeping legislation that will be the greatest shift in public policy in decades. Yes, we can bemoan the lack of a completely private enterprise driven system but the reality is Big Brother is here and he's not going away. Without a doubt there will be implications for investors that need to be considered; and it's not all bad news from an investment perspective.

  • Sanofi_whattowear.jpg

    Stacy and Clinton definitely had nothing to do with it, but Sanofi-Pasteur (the vaccines division of Sanofi-Aventis) greets visitors with a "What Not To Wear" brochure.

  • Before you attempt to game King Pharmaceuticals post earnings, check out our interview with CEO Brian Markison.

  • Swine Flu Needle

    New York City health officials scrambled to explain themselves Thursday following outraged media reports about bankers who got scarce H1N1 flu vaccines through their employers

  • merck_ad_logo_200.jpg

    I am not a Trekkie. In fact, sci-fi and fantasy are two of of my least favorite genres. But the Vulcan salutation was one of the first things I thought of when I went to the facelifted Merck Web site this morning to link to and print the press release about the new Merck.

  • lipitor_bottle_200.jpg

    Pfizer, or one of its ad agencies, is apparently putting out a casting call for a new Lipitor pitchman.

  • Over the past few days there's been a remarkable confluence of newsflow, most of it positive, out of biopharma. First the bad news.

  • obesity_man_200.jpg

    I end the week as I started it: blogging about Vivus and the three-contestant race to make a new prescription diet pill.

  • Stocks rallied Thursday, rebounding off of the prior session's rout, after reports showed the economy grew more than expected last quarter and jobless claims fell. The Dow jumped more than 2 percent—its best day since July.

  • On a day when the market is in full-tilt rally mode on the GDP number, shares of Dow component Merck and the company it's buying, Schering-Plough, are sliding. So, what gives?

  • Stocks rallied Thursday, rebounding off of the prior session's rout, after reports showed the economy grew more than expected last quarter and jobless claims fell.

  • Stocks rallied Thursday, rebounding off of the prior session's rout, after reports showed the economy grew more than expected last quarter and jobless claims fell.

  • Futures pointed to a positive open for Wall Street on Thursday ahead of the all-important U.S. third-quarter gross domestic product data.

  • Winterizing Your Portfolio - A CNBC Special Report

    Stocks tumbled to session lows late Wednesday, with the Dow down more than 100 points, as worries about the recovery gripped the market.

  • Winterizing Your Portfolio - A CNBC Special Report

    Stocks were lower at the halfway point Wednesday as investors shrugged off some good news and worries about the recovery gripped the market.

  • Stocksskidded Wednesday, despite a rise in durable-goods orders and some earnings beats, as worries about the recovery dragged on the market.

  • gsk_logo.jpg

    GlaxoSmithKline is one of the handful of drug companies on the front lines of the fight against the flu. In fact, it is the only company that has products on both sides. GSK makes a vaccine and an antiviral. In the third quarter, GSK today reported that it sold nearly $300 million worth of the inhalable flu-fighter Relenza. That’s a more than 10-fold increase from a year ago. And CEO Andrew Witty reportedly forecast around $1.6 billion worth of flu shot sales in the fourth quarter.

  • The weak consumer confidence report that hit U.S. stocks on Tuesday is having a lingering effect this Wednesday, with global stock markets falling and stock index futures pointing to another lower open on Wall Street.